Form D · Biotechnology

Dialectic Therapeutics, Inc.

Dallas, TX · CIK 0001750926

Offering snapshot reported Feb 11, 2021 · SEC filing

Reported sold: $6.35M
Investors reported: 27
Minimum accepted: $50K
First sale: Dec 15, 2020

Fundraising history

Reported sold

Dates are filing dates, not cash receipt dates. Decreases are reported revisions, not evidence of withdrawals. Separate offering histories are not added together.

What changed?

Latest filing versus its linked predecessor, where available.

Reported sold$2,925,000 → $6,350,000
Reported investors12 → 27
Minimum accepted$75,000 → $50,000

Filing history

Scroll to see all columns →

Filed	Filing type	Reported sold	Change vs linked filing	Investors	Source
Feb 11, 2021	Amendment	$6,350,000	$3,425,000vs Dec 29, 2020	27	SEC filing
Dec 29, 2020	Initial	$2,925,000	No comparison	12	SEC filing
Oct 6, 2020	Initial	$500,000	No comparison	12	SEC filing
Nov 13, 2018	Initial	$2,000,000	No comparison	2	SEC filing

Offering details

Securities: Debt, Option to acquire
Exemptions: 06b
Duration over one year: No
Business combination: No

Sales commissions: $0
Finders' fees: $0
Form D file number: 021-384660

Source: Form D, filed Feb 11, 2021. Minimum accepted may differ from a standard advertised minimum.

Fund connections

No confirmed ADV fund connection is available for this issuer.

People & organizations

Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.

People and organizations reported in Form D filings
Name	Reported role
David Genecov	Director, Executive
John D. Harkey	Director
Robert Hromas	Director
Joshua Sills	Executive
Daohong Zhou	Director

Issuer details

Industry: Biotechnology (See others in industry)

Address:

12200 N Stemmons Freeway Suite 100
Dallas, TX, 75234